Michel Zwaan, Prof. Dr.
Head Trial and Data Center · Princess Máxima Center · Princess Maxima Center for Pediatric Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michel Zwaan, Prof. Dr. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:36 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06262438 · CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML PatientsPrincess Maxima Center for Pediatric Oncology · recruiting · Acute Myeloid Leukemia in Children · study director
- Ph3NCT05994690 · CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML PatientsPrincess Maxima Center for Pediatric Oncology · recruiting · Acute Myeloid Leukemia in Children · study director
- Ph1/Ph2NCT05751044 · HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesPrincess Maxima Center for Pediatric Oncology · recruiting · Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent · study chair
- Ph1/Ph2NCT05745714 · HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesPrincess Maxima Center for Pediatric Oncology · recruiting · Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent · study chair
- Ph1/Ph2NCT05740449 · HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesPrincess Maxima Center for Pediatric Oncology · withdrawn · Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent · study chair
- Ph1/Ph2NCT05658640 · HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological MalignanciesPrincess Maxima Center for Pediatric Oncology · recruiting · Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent · study chair
- N/ANCT05270096 · International Leukemia Target BoardPrincess Maxima Center for Pediatric Oncology · recruiting · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 23 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in childhood acute lymphoblastic leukemia.